Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychiatr Serv 57:403-406, March 2006
doi: 10.1176/appi.ps.57.3.403
© 2006 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Huckans, M. S.
* Articles by Hauser, P.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Huckans, M. S.
* Articles by Hauser, P.
Related Collections
* Dual Diagnosis Patients
* Quality of Care, Practice Guidelines
* Other Health Services Issues
* Schizophrenia Spectrum Disorders

Brief Report

Management of Hepatitis C Disease Among VA Patients With Schizophrenia and Substance Use Disorders

Marilyn S. Huckans, Ph.D., Aaron D. Blackwell, B.A., Todd A. Harms, B.S. and Peter Hauser, M.D.

OBJECTIVE: Rates of hepatitis C (HCV) infection, testing, and treatment were compared among patients with schizophrenia, a substance use disorder, or co-occurring schizophrenia or schizoaffective disorder and a substance use disorder and a control group. METHODS: Information about 293,445 patients of the Northwest Veterans Healthcare Administration was obtained. RESULTS: The substance use disorder group constituted 13.6 percent of the sample; the schizophrenia group, 1.6 percent; and the co-occurring-disorders group, 1.4 percent. Respectively, these groups were approximately four, two, and six times as likely as the control group to receive HCV testing and about seven, two, and eight times as likely to be infected. The rate of interferon (IFN) therapy was significantly lower for the substance use group and the group with co-occurring disorders. However, the magnitude of the differences was not substantial, suggesting that these high-risk groups were not excluded from IFN therapy.




This article has been cited by other articles:


Home page
Schizophr BullHome page
M. Huckans, A. Mitchell, S. Ruimy, J. Loftis, and P. Hauser
Antiviral Therapy Completion and Response Rates Among Hepatitis C Patients With and Without Schizophrenia
Schizophr Bull, June 17, 2008; (2008) sbn065v1.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
O. Freudenreich, R. T. Gandhi, J. P. Walsh, D. C. Henderson, and D. C. Goff
Hepatitis C in Schizophrenia: Screening Experience in a Community-Dwelling Clozapine Cohort
Psychosomatics, October 1, 2007; 48(5): 405 - 411.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org